Using polyamide nucleic acid oligomers to engender a...

Details Using polyamide nucleic acid oligomers to engender a... Using polyamide nucleic acid oligomers to engender a...

2006-01-24

2006-01-24

McGarry, Sean (Department: 1635)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S006120, C435S377000, C435S455000, C514S04400A, C514S002600, C536S018700, C536S024100, C536S024500

Reexamination Certificate

active

06989270

ABSTRACT:
The invention involves methods and materials for extracellularly administering PNA oligomers to living cells. Specifically, the invention provides methods and materials of treating living cells with PNA oligomers such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. In addition, the invention provides methods and materials for orally administering PNA oligomers to animals such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. The invention also provides sense and antisense PNA oligomers that modulate transcription and translation, respectively. The invention also provides mismatch PNA oligomers that modulate the degree of an engendered biological response. In addition, the invention provides methods and materials for detecting PNA oligomers within a biological sample collected from an animal. Further, the invention provides methods and materials for screening potential PNA oligomers for the ability to engender a sequence specific biological response. Further, the invention provides methods of identifying the function of polypeptides and of determining the relative turnover rate of functional polypeptides.

REFERENCES:
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5470974 (1995-11-01), Summerton et al.
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5641625 (1997-06-01), Ecker et al.
patent: 5773571 (1998-06-01), Nielsen et al.
patent: 5783682 (1998-07-01), Cook et al.
patent: 5786461 (1998-07-01), Buchardt et al.
patent: 6156501 (2000-12-01), McGall et al.
patent: 6472209 (2002-10-01), Richelson et al.
patent: 6743627 (2004-06-01), Richelson et al.
patent: WO 92/20702 (1992-11-01), None
patent: WO 92/20703 (1992-11-01), None
patent: WO 95/01370 (1995-01-01), None
patent: WO 95/04748 (1995-02-01), None
patent: WO 95/04749 (1995-02-01), None
patent: WO 95/14789 (1995-06-01), None
patent: WO 96/35705 (1996-11-01), None
patent: WO 97/38013 (1997-10-01), None
patent: WO 97/41150 (1997-11-01), None
patent: WO 98/53801 (1998-12-01), None
patent: WO 99/05302 (1999-02-01), None
patent: WO 99/13719 (1999-03-01), None
patent: WO 99/13893 (1999-03-01), None
patent: WO 99/20643 (1999-04-01), None
McMahon et al. “Altering behavioral responses and dopamine transporter protein with antisense peptide nucleic acids” (submitted for publication) no date.
McMahon et al. Extracranial injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain (submitted for publication) no date.
McMahon et al. “Peptide Nucleic Acids Specifically Cause Antigene Effects in vivo” (submitted for publication).
Soomets et al., Frontiers in Biosciences vol. 4:782-786, Nov. 1, 1999.
Rezaei et al., Neurochemistry, vol. 12(2):317-320, Feb. 2001.
Rezaei K. et al., “Intrathecal Administration of PNA Targeting Galanin Receptor Reduces Galanin-Mediated Inhibitory Effect in the Rat Spinal Cord”,NeuroReportvol. 12 (2) 317-320 (2001).
Basu S. and Wickstrom E., “Synthesis and Characterization of a Peptide Nucleic Acid Conjugated to a D-Peptide Analog of Insulin-like Growth Factor 1 for Increased Cellular Uptake,”Bioconjugate Chem. 8:481-488 (1997).
Bonham et al., “An Assessment of the Antisense Properties of RNase H-Competent and Steric-Blocking Oligomers,”Nucleic Acids Res. 23:1197-1203 (1995).
Branch, A.D., “A good antisense molecule is hard to find”, TIBS, 23:45-50 (1998).
Corey D.R., “Peptide Nucleic Acids: Expanding the Scope of Nucleic Acid Recognition,”Trends in Biotech. 15:224-229 (1997).
Crooke S., Antisense Research and Applications, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, Berlin, Heidelberg, New York, Chapter 1, p. 2-50(1993).
Crooke, S., Antisense '97: A Roundtable on the state of the industry,Nature Biotechnology, 15:519-524 (1997).
Crooke S.T. et al., “Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in Mice,”J. Pharm. Exp. Ther. 277:923-937 (1996).
Demidov V.V. et al., “Stability of Peptide Nucleic Acids in Human Serum and Cellular Extracts,”Biochem. Pharmacol. 48:1310-1313 (1994).
Ecker, D.J. and Freier, S.M., “PNA, Antisense, and Antimicrobials”,Nature Biotechnology, 16:332 (1998).
Faruqi et al., “Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells”,Proc. Natl. Acad. Sci. USA, 95:1398-1403 (1998).
Fraser G.L. et al., “In Vivo Modulation of Gene Expression by a Peptide Nucleic Acid Oligomer Antisense to the δ-Opioid Receptor,” Abstracts—Society of Neuroscience23:267.4 (1997).
Gambacorti-Passerini C. et al., “In Vitro Transcription and Translation Inhibition by Anti-Promyelocytic Leukemia (PML)/Retinoic Acid Receptor α and Anti-PML Peptide Nucleic Acid,”Blood88:1411-1417 (1996).
Good L. and Nielsen P.E., “Progress in Developing PNA as a Gene-Targeted Drug,”Antisense Nucleic Acid Drug Dev. 7:431-437 (1997).
Good, L. and Nielsen, P.,E., “Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA”,Nature Biotechnology, 16:355-358 (1998).
Gray G.D. et al., “Transformed and Immortalized Cellular Uptake of Oligodeoxynucleoside Phosphorothioates, 3′ Alkylamino Oligodeoxynucleotides, 2′-O-methyl Oligoribonucleotides, Oligodeoxynucleoside Methylphosphonates, and Peptide Nucleic Acids,”Biochem. Pharmacol. 53:1465-1476 (1997).
Gura, T., “Antisense Has Growing Pains”,Science, 270:575-577 (1995).
Hanvey J.C. et al., “Antisense and Antigene Properties of Peptide Nucleic Acids,”Science258:1481-1485 (1992).
Hyrup B. and Nielsen P.E., “Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications,”Bioorg. Med. Chem. 4:5-23 (1996).
Knudsen H. and Nielsen P., “Application of Peptide Nucleic Acid in Cancer Therapy,”Anti-Cancer Drugs8:113-118 (1997).
Koppelhus U. et al., “Efficient In Vitro Inhibition of HIV-1 Gag Reverse Transcription by Peptide Nucleic Acid (PNA) at Minimal Ratios of PNA/RNA,”Nucleic Acids Res. 25:2167-2173 (1997).
Mardirossian K. et al., “In Vivo Hybridization of Technetium-99m-Labeled Peptide Nucleic Acid (PNA),”J. Nuc. Med. 38:907-913 (1997).
Nielsen P.E. et al., “Peptide Nucleic Acid (PNA). A DNA Mimic With a Peptide Backbone,”Bioconjugate Chem. 5:3-7 (1994).
Norton et al., “Inhibition of Human Telomerase Activity By Peptide Nucleic Acids”,Nat. Biotech., 14:615-618 (1996).
Pardridge W.M. et al., “Vector-Mediated Delivery of a Polyamide (“Peptide”) Nucleic Acid Analogue Through the Blood-Brain Barrier In Vivo,”Proc. Natl. Acad. Sci. USA92:5592-5596 (1995).
Peffer N.J. et al., “Strand-Invasion of Duplex DNA by Peptide Nucleic Acid Oligomers,”Proc. Natl. Acad. Sci. USA90:10648-10652 (1993).
Pooga et al., “Cell Penetrating PNA Constructs Regulate Galanin Receptor Levels and Modify Pain Transmission In Vivo”,Nature Biotech., 16:857-861 (1998).
Praseuth D. et al., “Peptide Nucleic Acids Directed to the Promoter of the α-Chain of the Interleukin-2 Receptor,”Biochim. Biophys. Acta. 1309:226-238 (1996).
Rossi G. et al., “Blockade of Morphine Analgesia by an Antisense Oligodeoxynucleotide Against the Mu Receptor,”Life Sciences54:PL375-PL379 (1994).
Scarfi S. et al., “Synthesis, Uptake, and Intracellular Metabolism of a Hydrophobic Tetrapeptide-Peptide Nucleic Acid (PNA)-Biotin Molecule,”Biochem. Biophys. Res. Commun. 236:323-326 (1997).
Senior, K., “Going FISHing with peptide—nucleic acid”,Molecular Medicine Today, p. 231 (1998).
Tanaka K. et al., “Structure and Functional Expression of the Cloned Rat Neurotensin Receptor,”Neuron4:847-854 (1990).
Ta

Affiliated with

Also associated with

Rating

Using polyamide nucleic acid oligomers to engender a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Using polyamide nucleic acid oligomers to engender a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Using polyamide nucleic acid oligomers to engender a... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3531366